

2 September 2019



Cancellation of Unlisted Options

Zelda Therapeutics Limited (ASX: ZLD, “the Company” or “Zelda”) wishes to advise the cancellation of the following unlisted options, issued under an Employee Share Option Plan (ESOP), as vesting conditions were not met:

Number	Details of Cancelled ESOP Options
2,103,333	Exercise price of \$0.10, vesting on 3 September 2019, expiring on 16 January 2022.

The Company’s current capital structure is as follows:

Number	Class
757,341,934	Ordinary shares
38,000,000	Unlisted options exercisable at \$0.03125 on or before 17 November 2021 held in escrow for 24 months from reinstatement to official quotation
2,000,000	Unlisted options exercisable at \$0.04 on or before 6 February 2020.
4,500,000	Unlisted options exercisable at \$0.04 on or before 6 February 2020 and subject to vesting conditions.
1,000,000	Unlisted options exercisable at \$0.125 on or before 22 August 2021.
2,000,000	Unlisted options exercisable at \$0.125 on or before 22 August 2021 and subject to vesting conditions.
3,596,667	Unlisted options exercisable at \$0.10 on or before 16 January 2022.
6,000,000	Unlisted options exercisable at \$0.10 on or before 16 January 2022 and subject to vesting conditions.
5,000,000	Unlisted options exercisable at \$0.10 on or before 19 February 2022.
5,000,000	Unlisted options exercisable at \$0.15 on or before 19 February 2022 and subject to vesting conditions.
5,000,000	Unlisted options exercisable at \$0.20 on or before 19 February 2022 and subject to vesting conditions.
5,000,000	Unlisted options exercisable at \$0.28 on or before 19 February 2022 and subject to vesting conditions.
5,000,000	Unlisted options exercisable at \$0.30 on or before 19 February 2022 and subject to vesting conditions.

ENDS



About Zelda Therapeutics (www.zeldatherapeutics.com)

Zelda Therapeutics Ltd is an Australian-based bio-pharmaceutical company developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions. The Company is undertaking:

- A **human clinical trial program** focused on insomnia, autism and opioid reduction with activities in Australia and the USA.
- A **pre-clinical research program** examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

The company conducts this work in partnership with world-leading researchers and organisations including Complutense University in Madrid, Spain; Curtin University in Perth, Western Australia; the Telethon Kids Institute in Perth; the University of Western Australia, in Perth; St. Vincent's Hospital in Melbourne, Australia; and the Children's Hospital of Philadelphia (CHOP) in the United States.

Zelda has also formed a strategic partnership with European medicinal cannabis group HAPA Medical BV, to access HAPA's EU- GMP grade manufacturing capabilities and accessing its German distribution network providing a credible and rapid path to commercialisation for successful clinically validated formulations.